Additive effects of captopril and losartan on blood pressure in mildly sodium-depleted normotensives

Clinical Drug Investigation

Volumn 14, Issue 4, 1997, Pages 321-325

  Sommers, De Klerk ^a   Van Wyk, Marieta ^a   Snyman, Jacques R ^a  

^a UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; CAPTOPRIL; LOSARTAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; HEART RATE; HUMAN; HUMAN EXPERIMENT; MALE; MEAN ARTERIAL PRESSURE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SODIUM DEPLETION;

EID: 0030717676     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199714040-00011     Document Type: Article

References (21)

1. Swartz SL, Williams GH, Hollenburg NK, et al. Converting enzyme inhibition in essential hypertension: the hypotensive response does not reflect only reduced angiotensin II formation. Hypertension 1974; 1: 106-11
2. Wiener G, Schölkens BA, Becker RHA, et al. Ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endothelium-derived bradykinin. Hypertension 1991; 18: 558-63
3. Danckwardt L, Shimizu I, Bönner G, et al. Converting enzyme inhibition in kinin-deficient Brown Norway rats. Hypertension 1990; 16: 429-35
4. Waeber B, Aubert JF, Vavrek R, et al. Role of bradykinin in blood pressure regulation of conscious spontaneously hypertensive rats. J Hypertens 1986; 4 Suppl. 6: S597-8
5. Bao G, Gohlke P, Qadri F, et al. Chronic kinin receptor blockade attenuates the antihypertensive effect of ramipril. Hypertension 1992; 20: 74-9
6. Wong PC, Price WA, Chiu AT, et al. Hypotensive action of DuP 753, an angiotensin II antagonist, in spontaneously hypertensive rats. Hypertension 1990; 15: 459-68
7. Cachofeiro V, Sakakibara T, Nasjletti A. Kinins, nitric oxide, and the hypotensive effect of captopril and ramiprilat in hypertension. Hypertension 1992; 19: 138-45
8. Azizi M, Catellier G, Guyene T-T, et al. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation 1995; 92: 825-34
9. McGregor GA, Markandu ND, Smith SJ, et al. Maintenance of blood pressure by the renin-angiotensin system in normal man. Nature 1981; 291: 329-31
10. Erdös EG. Angiotensin I converting enzyme. Circ Res 1975; 36: 247-55
11. Erdös EG. Angiotensin I converting enzyme and the changes in our concepts through the years. Hypertension 1990; 16: 363-70
12. Lantz I, Terenius L. High enkephalyl peptide degradation due to angiotensin-converting enzyme-like activity in human CSF. FEBS Lett 1985; 193: 31-4
13. Ujhelyi MR, Ferguson RK, Vlasses PH. Angiotensin-converting enzyme inhibitors: mechanistic controversies. Pharmacotherapy 1989; 9: 351-62
14. Gavras I, Gavras H. Role of bradykinin in hypertension and the antihypertensive effect of angiotensin-converting enzyme inhibitors. Am J Med Sci 1988; 295: 305-7
15. Scicli AG, Mindroiu T, Scicli GM, et al. Blood kinins, their concentration in normal subjects and in patients with congenital deficiency in plasma prekallikrein and kininogen. J Lab Clin Med 1982; 100: 81-93
16. Bonner G, Preiss S, Schunk U, et al. Hemodynamic effects of bradykinin on systemic and pulmonary circulation in healthy and hypertensive humans. J Cardiovasc Pharmacol 1990; 15 Suppl. 6: S46-56
17. 2 receptor antagonism on the hypotensive effects of ACE inhibition. Br J Pharmacol 1994; 113: 717-22
18. Doig JK, MacFadyen RJ, Sweet CS, et al. Dose-ranging study of the angiotensin type I receptor antagonist losartan (DuP 753/MK 954) in salt-depleted normal man. J Cardiovasc Pharmacol 1993; 21: 732-8
19. Cirollo VJ, Gomez HJ, Salonen J, et al. Lisinopril: dose-peak effect relationship in essential hypertension. Br J Clin Pharmacol 1988; 25: 533-8
20. Nelson E, Arcuri K, Ikeda L, et al. Efficacy and safety of losartan in patients with essential hypertension [abstract]. Am J Hypertens 1992; 5: 19A
21. Goa KL, Wagstaff AJ. Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Drugs 1996; 51: 820-45